Status: Not yet recruiting
EFG vs IVIG in TAMG
This study is a prospective, multi-center, randomized controlled study to evaluate the efficacy and safety of efgartigimod (EFG) and intravenous immunoglobulin (IVIG) in the perioperative application for acetylcholine receptor (AChR) antibody-positive thymoma patients with myasthenia gravis in order to provide reliable evidence for clinical decision-making.
Participants needed: 64
Trial details
Phase: Phase 3Age: 18-75Biological sex: AllType: InterventionalSponsor: Shanghai Zhongshan HospitalUpdated: Nov 17, 2025Locations: 1
Eligibility criteria
Patients aged >18 years and ≤75 years, with an expected survival time >12 months... [+7]
MGFA type V; [+15]